News

June 24, 2015

ICAAC2015_Fina2l

The UNTHSC Pre-Clinical Services group will be in attendance at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in San Diego, CA (September 17 – 21, 2015) and welcomes the opportunity to meet with current as well as prospective collaborators to discuss ongoing and future projects. If interested, please contact William Weiss (817-735-2111 or william.weiss@unthsc.edu) to arrange for a convenient dayand time to meet.

 

 

January 30, 2015

WH seal

President’s 2016 budget proposes historic investment to combat antibiotic-resistant bacteria to protect public health.

“We now have a national strategy to combat antibiotic-resistant bacteria, to better protect our children and grandchildren from the reemergence of diseases and infections that the world conquered decade ago”

– President Barack Obama’s remarks at the Global Health Security Agenda Summit, regarding the Executive Order to Combat Antibiotic Resistance, September 26, 2014.

http://www.whitehouse.gov/the-press-office/2015/01/27/fact-sheet-president-s-2016-budget-proposes-historic-investment-combat-a

January 27, 2015

eccmid image

The 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) meeting will be held from April 25-28, 2015 in Copenhagen, Denmark. The meeting will feature a series of keynote lectures, symposia, educational workshops and meet-the-experts sessions on parallel tracks, covering the entire field of infectious diseases and clinical microbiology. Among the presentations will be:

Evaluating the induction potential of three antibiotics in the hamster Clostridium difficile infection model.

M. Pulse, T. Murphy, P. Nguyen, K. Peterson, J. Silva, J. Simecka, D. Valtierra, W. Weiss, S. Sayah-Jeanne, J. de Gunzburg

UNT Health Science Center, Fort Worth, TX & Dalvolterra, Paris, France

Efficacy evaluation of TP-271, a novel fluorocycline, in a neutropenic murine pneumonia model against susceptible and resistant gram-positive pathogens

W. Weiss, T. Murphy, M. Pulse, P. Nguyen, D. Valtierra, K. Peterson, J. Silva, J. Simecka, J. Sutcliffe, T. Grossman

UNT Health Science Center, Fort Worth, TX & Tetraphase Pharmaceuticals, Watertown, MA

Synthetic novel host defense protein mime tics for the treatment of gram-negative bacterial infections

S. Ram, K. Menon, R. Scott, D. Weaver, K. Freeman, G. Tew, W. Weiss, W. DeGrado, K. Fadela, A. Kumar, D. Brennan, S. Holden

Fox Chase Chemical Diversity Center, Doylestown, PA & UNT Health Science Center, Fort Worth, TX

www.eccmid.org

January 15, 2015

SMI

UNTHSC PreClinical Services to present at the SMI 17th Annual conference on SuperBugs & SuperDrugs, March 25-26, 2015 in London, UK.

The Changing Role of Academia in Drug Discovery

  • Historical perspective of academic involvement in drug development
  • Growth of the modern pharmaceutical industry and detachment from academia
  • Downturn in antibacterial discovery and development and current needs
  • Collaboration of industry and academia in drug discovery
  • Novel partnering models to increase innovation

William Weiss, Director of PreClinical Services, UNT Health Science Center

www.smi-online.co.uk/pharmaceuticals/uk/superbugs-superdrugs

July 3, 2014

IC14

The UNTHSC Pre-Clinical Services group will be in attendance at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington DC (September 59, 2014) and welcomes the opportunity to meet with current as well as prospective collaborators to discuss ongoing and future projects. If interested, please contact William Weiss (817-735-2111 or william.weiss@unthsc.edu) to arrange for a convenient dayand time to meet.

In addition, please plan on attending the following presentations:

Poster Session 172 New Spins on Protein Synthesis Inhibitors

Monday, Sept. 08, 2014; 11:00am – 1:00pm

Pharmacodynamic evaluation of TP-271, a novel fluorocycline, in a neutropenic murine lung model infected with Streptococcus pneumoniae presentedby Tim Murphy

Pharmacodynamics of the fluorocycline TP-271 in a neutropenic murine lung infection model with methicillin-resistant Staphylococcus aureus presentedby Bill Weiss

Slide Session 200Clostridium difficile : Pathogenesis, Immune Response and Therapy

Monday, Sept. 08, 2014; 4:00pm – 4:15pm

Epidemic Clostridium difficile ribotype 027 strains are more virulent than other non-epidemic strains in the hamster CDAD model presented by MarkPulse

April 24, 2014

ESMID

The UNTHSC Pre-Clinical Services group will be attending the 24th ECCMID meeting in Barcelona, Spain from May 9-14 and welcomes the opportunity to meet with interested parties. Please contact William Weiss (817-735-2111 or william.weiss@unthsc.edu) to arrange for a convenient day and time tomeet.

In addition, please stop by the following poster presentations:

Saturday May 10th 3:30pm: Poster P0112 Ileal Dosing of Nisin and Miconazole Combination is Efficacious in the Hamster Clostridium difficile Associated Disease Model (Presented by Mark Pulse, Assistant Director UNTHSC Pre-Clinical Services).

Sunday May 11th 1:30pm: Poster 0804 DAV131, an oral absorbent-based product, exerts dose-dependent protection of hamsters againstmoxifloxacin-induced Clostridium difficile lethal infection (Presented by DaVolterra in conjunction with UNTHSC).

March 1, 2014

SMI presents Superbugs & Superdrugs A Focus on Antibacterials

May 5 6, 2014, London, UK

“Research and Development in Neglected Diseases” (presented by William Weiss, Director of UNTHSC Pre-Clinical Services)

Overview and Clinical Relevance

Current therapies and issues

Why pursue research of neglected diseases?

New efforts and treatment options

June 7, 2013

The UNTHSC Pre-Clinical Services group will be in attendance at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Denver, Colorado (September 10-13, 2013) and welcomes the opportunity to meet with current Sponsors as well as prospective collaborators to discuss ongoing and future projects. If interested, please contact William Weiss (817-735-2111 or william.weiss@unthsc.edu) to arrange for a convenient day and time to meet.

In addition, please plan on attending the following presentations by Mark Pulse, Assistant Director of the Pre-Clinical Services group:

Wednesday, Sept 11. – Slide Session 066 – Clostridium difficile: Pathogenesis

10:00 – 10:15 am : Dosing clindamycin before and after infection dramatically impacts disease outcome in the hamster Clostridium difficile -associated disease model

Thursday, Sept. 12 Poster Session 143 Antimicrobial Resistance and Immune Therapy

11:00am1:00 pm : Characterization of the programmed death 1 (PD1) and its ligand, PD-L1, in a murine cecal ligation model of sepsis

April 27, 2013

23rd ECCMID Meeting, Berlin, Germany

Oral Session New Antibacterial agents

In vivo Efficacy of the novel monosulfactam BAL300072 alone and in combination with meropenem against clinically important gram-negative pathogens

William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

March 1, 2013


SMI Presents: Superbugs & SuperdrugsA Focus on Antibacterials
4th March to 5th March 2013, London, UK

AN UPDATE ON CURRENT ISSUES AND PROGRESS IN C. DIFFICILE DISEASE (CDAD)
William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center

  • A brief history and review
  • The changing epidemiology and resistance development in CDAD
  • Transmission, Virulence factors and clinical manifestations
  • Surveillance, diagnosis and clinical testing
  • Prevention, emerging therapies and potential for efficacy

November 12, 2012

UNTHSC Pre-Clinical Services (PCS) is pleased to announce the recent hire of Timothy Murphy who joins the group as Project Manager.

Tim comes to the group with 16 years experience in the drug discovery and pharmacology industry. He has previously held positions of increasing responsibility in ViviSource Laboratories, Arpida Inc., Enanta Pharmaceuticals and Wyeth Research. Tim brings with him extensive experience and expertise in the design and performance of anti-infective efficacy models: antibacterial and antiviral, pharmacology and oncology studies as well asPK/PD evaluations and vaccine discovery research. He has earned both B.S. and M.S. degrees in biology and has co-authored or presented numerousmanuscripts and presentations.

UNTHSC PCS welcomes Tim and looks forward to the contributions that he will make along with expanding the expertise and scope of testing that thegroup has to offer to our Sponsors.

July 30, 2012

The UNTHSC Pre-Clinical Services group will be in attendance at the 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICCAC) inSan Francisco, CA (September 9 12, 2012) and welcomes the opportunity to meet with current collaborators as well as prospective Sponsors to discussongoing and future research projects, utilizing our expertise to meet your R & D requirements. If interested, please contact William Weiss (817-725-2111or william.weiss@unthsc.edu) to arrange for a convenient day and time to meet.

April 2, 2012

UNTHSC Pre-Clinical services, in conjunction with Affinium Pharmaceuticals, presented their findings on the effects of AFN-1252, a novel fatty acidbiosynthesis inhibitor antibacterial agent, on the in vitro and in vivo expression of S. aureus virulence genes at the 22nd European Congress of ClinicalMicrobiology and Infectious Disease (ECCMID) in London, UK.

Presentation Summary: (full details and time can be found on the ECCMID Congress website)

Poster P2058 AFN-1252 Alters In Vitro and In Vivo Staphylococcus aureus Gene Expression and Reduces Bacterial Counts in a Mouse GranulomaInfection Model

M. E. Pulse1, N. Kaplan2, J. Parsons3, C. O. Rock3, M. Kukula1, P. Nguyen1, J. Pierce1, D. Valtierra1, W. J. Weiss1, J. W. Simecka1

1UNTHSC, Fort Worth, TX, 2Affinium Pharmaceuticals, Toronto, Canada, 3St. Jude Children’s Res. Hosp., Memphis, TN

Exposure of S. aureus cultures to AFN-1252 resulted in the anticipated up-regulation of genes involved in the FAS II pathway associated with the FapRregulon and the unpredicted down-regulation of several virulence genes that are controlled by the SaeRS two-component regulator. In the MG infectionmodel, a single oral dose of AFN-1252 at 2 hours post-infection resulted in mean log10 CFU reductions of 2.9 3.1 in 24 48 hours after dosing. PKanalysis of this fluid revealed that the relative exposure (AUC) of AFN-1252 in the granuloma fluid was 85% of the corresponding plasma levels, andqRT-PCR of S. aureus RNA extracted from granuloma fluid indicated that fabH expression was up-regulated and virulence factor expression was down-regulated following the single dose of AFN-1252. AFN-1252 was also dosed consecutively (2, 26, 50 hours) in the MG model, which maximally reducedgranuloma-associated S. aureus counts by 5.3 log10 CFU within 72 hours of the first dose. AFN-1252 triggered the up-regulation of genes associated with the FASII pathway in S. aureus, and it simultaneously down-regulated virulence genes controlled by the SaeRS regulator. AFN-1252 not only alteredS. aureus gene expression in the granuloma fluid, but it also therapeutically reduced the CFU counts in the fluid as well.